TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01500018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 8 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 16 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 16 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 16 mg
Study: NCT01566968

Intervention type: OTHER
Intervention: Cough challenge test
Description: Cough challenge will be performed with Capsaicin, citric acid and prostaglandin E2.

Intervention type: OTHER
Intervention: Cough challenge test
Description: Cough challenge will be performed with Capsaicin, citric acid and prostaglandin E2.

Intervention type: OTHER
Intervention: Cough challenge test
Description: Cough challenge will be performed with Capsaicin, citric acid and prostaglandin E2.

Intervention type: OTHER
Intervention: Cough challenge test
Description: Cough challenge will be performed with Capsaicin, citric acid and prostaglandin E2.

Intervention type: OTHER
Intervention: Cough challenge test
Description: Cough challenge will be performed with Capsaicin, citric acid and prostaglandin E2.

Intervention type: OTHER
Intervention: 24 hour ambulatory cough recording
Description: Cough recording by using an ambulatory sound recording device.

Intervention type: OTHER
Intervention: 24 hour ambulatory cough recording
Description: Cough recording by using an ambulatory sound recording device.

Intervention type: OTHER
Intervention: 24 hour ambulatory cough recording
Description: Cough recording by using an ambulatory sound recording device.

Intervention type: OTHER
Intervention: 24 hour ambulatory cough recording
Description: Cough recording by using an ambulatory sound recording device.

Intervention type: OTHER
Intervention: 24 hour ambulatory cough recording
Description: Cough recording by using an ambulatory sound recording device.

Intervention type: OTHER
Intervention: Cough quality of life questionnaire
Description: questionnaire designed to assess impact of cough on a person's life
Study: NCT02944032

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobymax
Description: MobyMax's Reading Stories program is a program that focuses on reading comprehension skills. Participants will start their training with stories that are matched to their reading grade level. Each grade contains 30 lessons, with 3 stories in each lesson. Participants are given questions to answer at the conclusion of each story, and children advance or remain at that level depending on the progression of their reading skill. Participants randomized to this program will be asked to train 30-45 minutes per session for 25 training sessions over a 5 to 9 week period.
Study: NCT02428517

Intervention type: PROCEDURE
Intervention: AlloHCT for Young/MSD
Description: Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Cyclophosphamide 60 mg/kg (D-3 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)

Intervention type: PROCEDURE
Intervention: AlloHCT for Young/MUD&FMD
Description: Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)

Intervention type: PROCEDURE
Intervention: AlloHCT for Old/MSD
Description: Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)

Intervention type: PROCEDURE
Intervention: AlloHCT for Old/MUD&FMD
Description: Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
Study: NCT02599714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: The triplet combination will be comprised of AZD2014 + palbociclib + fulvestrant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: The triplet combination will be comprised of AZD2014 + palbociclib + fulvestrant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: cyclin dependent kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: cyclin dependent kinase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant hormonal therapy as background

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant hormonal therapy as background
Study: NCT02556554

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G4 or G5 Platinum CGM system
Description: Intervention arm using the Dexcom G4 or G5 Platinum® CGM system during pregnancy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G4 or G5 Platinum CGM system with Share
Description: Treatment arm using the Dexcom G4 or G5 Platinum® CGM system with Share™
Study: NCT02951065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tooth brush without nylon bristles
Description: Subjects will use a bristle-less tooth brush. Subjects in both arms of the study will use the same waxed, mint-flavored floss; baking-soda based tooth paste; exams and professional tooth cleaning every 3-4 months; oral hygiene instruction every 3-4 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tooth brush with soft nylon bristles
Description: Subjects will use a soft bristled tooth brush. Subjects in both arms of the study will use the same waxed, mint-flavored floss; baking-soda based tooth paste; exams and professional tooth cleaning every 3-4 months; oral hygiene instruction every 3-4 months
Study: NCT03651869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cigarette 1
Description: Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cigarette 1
Description: Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cigarette 2
Description: Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cigarette 2
Description: Cigarette containing between 0mg nicotine and the conventional amount of nicotine (0.8mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patch 1
Description: A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patch 1
Description: A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patch 2
Description: A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patch 2
Description: A patch containing between 0mg nicotine and the conventional amount of nicotine (21mg)
Study: NCT01334164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Management Checkups
Description: Women assigned to the RMC condition met with a linkage manager after each research interview. When a woman reported substance use, HIV risk behavior or illegal activity, the linkage manager used motivational interviewing to: provide feedback regarding her current substance use, HIV risk behavior or illegal activity, discuss barriers that prevented her from stopping each activity and ways of avoiding them in the future, and assess and discuss her level of motivation for change. Linkage managers also scheduled treatment appointments, accompanied the women to treatment intake and stayed through the process and implemented an Engagement and Retention Protocol designed to improve retention rates. For women who refused the treatment option, the linkage manager and participant agreed upon an Alternative Action plan, which included various behaviors the woman had agreed to engage in to reduce or stop her substance use, HIV risk, or her participation in illegal activity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Outcome Monitoring
Description: Outcome monitoring only, however participates are still able (and do) enter treatment on their own
Study: NCT01577680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled GSK573719/vilanterol
Description: All subjects will receive a single dose of GSK573719/VI (125mcg/25mcg) in Treatment Period 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled GSK573719/vilanterol
Description: All subjects will receive a single dose of GSK573719/VI (125mcg/25mcg) in Treatment Period 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled GSK573719
Description: All subjects will receive GSK573719 (125mcg) once daily for seven days in Treatment Period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled GSK573719
Description: All subjects will receive GSK573719 (125mcg) once daily for seven days in Treatment Period 2
Study: NCT01133873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propoxyphene napsylate (XP20C)
Description: 100 mg capsules 6 times a day in ascending doses until a maximum tolerated dose is identified

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 times a day in ascending doses until a maximum tolerated dose is identified
Study: NCT01500018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 16 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 16 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 16 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 16 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 16 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 16 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 16 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 16 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 16 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 16 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-5214
Description: Single oral dose of 16 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 90 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 90 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 90 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 90 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 90 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 90 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 90 mg
Study: NCT04489628

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 or Placebo
Description: ): Participants will be given 8 capsules of either cholecalciferol 50,000 IU or placebo at study randomization. Participants will be instructed to take 4 capsules on receipt of the treatment package(Day 0), 2 capsules on Day 5, 1 capsule on Day 10, and 1 capsule on Day 15. A phone or text reminder will be included at Days 5, 10, and 15 to take the additional doses of vitamin D.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Doctella telehealth monitoring
Description: Doctella device will be give to participants by the Emergency department as part of usual care to monitor heart rate, respiratory rate, oxygen saturation, and perfusion index vitals continuously for approximately 10 days. The study team will receive the vitals signs data (heart rate, respiratory rate, oxygen saturation, perfusion index, and temperature) retrospectively and will not be able to monitor patients in real time.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Doctella telehealth monitoring
Description: Doctella device will be give to participants by the Emergency department as part of usual care to monitor heart rate, respiratory rate, oxygen saturation, and perfusion index vitals continuously for approximately 10 days. The study team will receive the vitals signs data (heart rate, respiratory rate, oxygen saturation, perfusion index, and temperature) retrospectively and will not be able to monitor patients in real time.
Study: NCT01500018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 90 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 90 mg
Study: NCT01566968

Intervention type: OTHER
Intervention: Cough quality of life questionnaire
Description: questionnaire designed to assess impact of cough on a person's life

Intervention type: OTHER
Intervention: Cough quality of life questionnaire
Description: questionnaire designed to assess impact of cough on a person's life
Study: NCT01500018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 90 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 90 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Single oral dose of 90 mg
Study: NCT00440011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03% eye drops
Description: bimatoprost 0.03% 1 drop nightly for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: travoprost 0.004% eye drops
Description: travoprost 0.004% 1 drop nightly for 3 months
Study: NCT03487848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Specified dose on specified days for specified duration
Study: NCT03872635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral carbohydrate liquid
Description: patients undergoing neoadjuvant chemotherapy and radical hysterectomy with bilateral pelvic lymph node dissection were randomized to receive 300mL of an oral carbohydrate liquid supplement 2 hour before surgery
Study: NCT04030533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab (SC): Dose 1
Description: Participants will receive a single dose of guselkumab (dose 1) subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab (SC): Dose 2
Description: Participants will receive a single dose of guselkumab (dose 2) subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab (IV): Dose 1
Description: Participants will receive a single IV infusion of guselkumab (dose 1).
Study: NCT02564237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: StreptAnova™ (Group A streptococcal (GAS) vaccine)
Description: StreptAnova™ vaccine - 30-valent plus Spa group A Streptococcal vaccine
Study: NCT04030533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab (IV): Dose 2
Description: Participants will receive a single IV infusion of guselkumab (dose 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 6 mg/mL
Description: Participants will receive a single IV infusion of ustekinumab 6 mg/mL solution.
Study: NCT03487848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Specified dose on specified days for specified duration
Study: NCT01519102

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual Hormone closed-loop system
Description: The closed-loop system is composed of three components: continuous glucose system, insulin infusion pumps that infuses insulin and glucagon and a control algorithm that decides on the infusion rates based on sensor readings.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dual Hormone closed-loop system
Description: The closed-loop system is composed of three components: continuous glucose system, insulin infusion pumps that infuses insulin and glucagon and a control algorithm that decides on the infusion rates based on sensor readings.
Study: NCT02162355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634 50 mg
Description: 2 tablets of 25 mg GLPG0634 once daily for 10 days
Study: NCT03281616

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Individually tailored diets; 30% caloric reduction according to daily energy requirements measured by indirect calorimetry

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Individually tailored diets; 30% caloric reduction according to daily energy requirements measured by indirect calorimetry
Study: NCT04266912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV
Study: NCT02162355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634 100 mg
Description: 1 tablet of 100 mg GLPG0634 once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634 200 mg
Description: 2 tablets of 100 mg GLPG0634 once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0634 200 mg
Description: 2 tablets of 100 mg GLPG0634 once daily for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 or 2 matching placebo tablets once daily for 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 or 2 matching placebo tablets once daily for 10 days
Study: NCT02564237

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B vaccine
Description: Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine
Description: Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Papillomavirus vaccine
Description: Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
Study: NCT03857048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Loss
Description: 12-wk weight loss intervention using a meal replacement strategy (Health \& Nutrition Technology, Carmel, CA), with an 8-10% weight loss goal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight Loss
Description: 12-wk weight loss intervention using a meal replacement strategy (Health \& Nutrition Technology, Carmel, CA), with an 8-10% weight loss goal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 16-wk supervised endurance exercise training program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Overfeeding
Description: 3-day hypercaloric diet designed to overfeed by 40% above total daily energy requirements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overfeeding
Description: 3-day hypercaloric diet designed to overfeed by 40% above total daily energy requirements

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Overfeeding
Description: 3-day hypercaloric diet designed to overfeed by 40% above total daily energy requirements
Study: NCT02323867

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha Beta T cell depletion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha Beta T cell depletion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha Beta T cell depletion
Study: NCT01186471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A643 (nicotine)
Description: 1mg oromucosal nicotine spray- three times daily during each treatment period

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A643 (nicotine)
Description: 2mg oromucosal nicotine spray- three times daily during each treatment period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo - three times daily during each treatment period
Study: NCT04266912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV
Study: NCT01241916

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Static-Progressive Splint
Description: Static progressive splinting is a well-established adjunct for restoring elbow motion. Such splints apply a static stress relaxation force to the elbow tissues, which is sequentially increased, as motion is achieved.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Splint
Description: Dynamic splints are a popular alternative, and apply a constant prolonged force to the tissues as additional motion is achieved.